Atara Biotherapeutics (NASDAQ:ATRA) Full Year 2023 Results

Key Financial Results

• Net loss: US$276.1m (loss widened by 21% from FY 2022).
• US$2.61 loss per share (further deteriorated from US$2.24 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Atara Biotherapeutics Revenues Disappoint

Revenue missed analyst estimates by 53%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 3.7% from a week ago.

Risk Analysis

We should say that we've discovered 6 warning signs for Atara Biotherapeutics (3 are a bit concerning!) that you should be aware of before investing here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.